US FDA’s Coronavirus Workload Shifting Beyond Idea Stage
Executive Summary
Pre-IND inquiries are slowing and the FDA says more late-stage development work is coming.
You may also be interested in...
Is Even The Pharma Industry Over COVID-19 Already?
Data suggests fewer approvals and new product ideas, as the business case for new generic and brand treatments seems to be tougher to make now than at other times during the pandemic.
US FDA Pandemic Performance: On-Time Decision Rates Improve; COVID Applications, Supplements Drop
Biosimilars continue their erratic behavior, with the low numbers driving big swings.
COVID-19 Supplement Approvals Jump, Some On-Time Decision Rates Slip For US FDA
In FY '21 third quarter, on-time decision rate improved for generics and biosimilars, but dropped again for new drug applications.